Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Long-Term Use of Azathioprine in the Management of Autoimmune Hepatitis.

Peters MG.

Gastroenterol Hepatol (N Y). 2019 May;15(5):277-279. No abstract available.

2.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):521-534. doi: 10.1016/j.cld.2019.04.012. Epub 2019 Jun 5. Review.

PMID:
31266625
3.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.

Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):511-519. doi: 10.1016/j.cld.2019.04.011. Epub 2019 Jun 6. Review.

PMID:
31266624
4.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):493-509. doi: 10.1016/j.cld.2019.04.010. Epub 2019 Jun 6. Review.

PMID:
31266623
5.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):487-492. doi: 10.1016/j.cld.2019.04.009. Epub 2019 Jun 6. Review.

PMID:
31266622
6.

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT; Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

Clin Infect Dis. 2019 Mar 28. pii: ciy913. doi: 10.1093/cid/ciy913. [Epub ahead of print]

PMID:
31220220
7.

Metabolic syndrome and liver steatosis occur at lower body mass index in US Asian patients with chronic hepatitis B.

Clarke WT, Miranda J, Neidich E, Hudock R, Peters MG, Kelly EM.

J Viral Hepat. 2019 Oct;26(10):1164-1169. doi: 10.1111/jvh.13147. Epub 2019 Jun 20.

PMID:
31134715
8.

Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.

Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA.

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):71-80. doi: 10.1097/QAI.0000000000002094.

PMID:
31107304
9.

HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.

Nápoles TM, Batchelder AW, Lin A, Moran L, Johnson MO, Shumway M, Luetkemeyer AF, Peters MG, Eagen KV, Riley ED.

J Public Health (Oxf). 2019 May 2. pii: fdz045. doi: 10.1093/pubmed/fdz045. [Epub ahead of print]

PMID:
31044248
10.

Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature.

Bowlus CL, Yang GX, Liu CH, Johnson CR, Dhaliwal SS, Frank D, Levy C, Peters MG, Vierling JM, Gershwin ME.

J Autoimmun. 2019 Jul;101:26-34. doi: 10.1016/j.jaut.2019.04.005. Epub 2019 Apr 24. Review.

PMID:
31027870
11.

Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma.

Yun SJ, Liu S, Buckley M, Wang T, Jin S, Karakousis G, Peters MG, Elder DE, Gimotty PA, Xu X.

Hum Pathol. 2019 Jun;88:78-86. doi: 10.1016/j.humpath.2019.03.008. Epub 2019 Apr 6.

PMID:
30965022
12.

Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States.

Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG.

Open Forum Infect Dis. 2018 Dec 26;6(1):ofy353. doi: 10.1093/ofid/ofy353. eCollection 2019 Jan.

13.

Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences.

Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED.

AIDS Care. 2019 Nov;31(11):1340-1347. doi: 10.1080/09540121.2019.1587353. Epub 2019 Mar 4.

PMID:
30829533
14.

Optical Clearing of Vaginal Tissues in Cadavers.

Chang CH, Hardy LA, Peters MG, Bastawros DA, Myers EM, Kennelly MJ, Fried NM.

Proc SPIE Int Soc Opt Eng. 2018 Jan-Feb;10468. pii: 104680K. doi: 10.1117/12.2285079. Epub 2018 Feb 7.

15.

Hepatitis B Virus Infection: What Is Current and New.

Peters MG.

Top Antivir Med. 2019 Jan;26(4):112-116.

16.

Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.

Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P.

Gastroenterology. 2019 Apr;156(5):1496-1507.e7. doi: 10.1053/j.gastro.2018.12.014. Epub 2018 Dec 26.

PMID:
30593799
17.

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K.

Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.

18.

Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway.

Fernández D, Guereño M, Lago Huvelle MA, Cercato M, Peters MG.

J Cancer Res Clin Oncol. 2018 Dec;144(12):2399-2418. doi: 10.1007/s00432-018-2751-0. Epub 2018 Sep 28.

PMID:
30267212
19.

Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now.

Jhaveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM.

Clin Infect Dis. 2018 Oct 30;67(10):1493-1497. doi: 10.1093/cid/ciy586.

PMID:
30215670
20.

An Assessment of the Clinical Accuracy of Ultrasound in Diagnosing Cirrhosis in the Absence of Portal Hypertension.

Kelly EMM, Feldstein VA, Parks M, Hudock R, Etheridge D, Peters MG.

Gastroenterol Hepatol (N Y). 2018 Jun;14(6):367-373.

21.

A Tough Egg to Crack.

Geha RM, Dhaliwal G, Peters MG, Manesh R.

J Hosp Med. 2018 Sep;13(9):641-645. doi: 10.12788/jhm.3063.

PMID:
30157286
22.

Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG; VHICS Study Team.

Open Forum Infect Dis. 2018 Jun 4;5(6):ofy103. doi: 10.1093/ofid/ofy103. eCollection 2018 Jun.

23.

Hepatitis B virus infection.

Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL.

Nat Rev Dis Primers. 2018 Jun 7;4:18035. doi: 10.1038/nrdp.2018.35. Review.

PMID:
29877316
24.

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.

MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119. doi: 10.1093/jac/dky146.

25.

Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy.

Willis SJ, Cole SR, Westreich D, Edmonds A, Hurt CB, Albrecht S, Anastos K, Augenbraun M, Fischl M, French AL, Kalapila AG, Karim R, Peters MG, Plankey M, Seaberg EC, Tien PC, Adimora AA.

AIDS. 2018 Mar 13;32(5):653-661. doi: 10.1097/QAD.0000000000001745.

26.

Human immunodeficiency virus and liver disease: A comprehensive update.

Sherman KE, Peters MG, Thomas D.

Hepatol Commun. 2017 Nov 6;1(10):987-1001. doi: 10.1002/hep4.1112. eCollection 2017 Dec.

27.

Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study.

Kelly EM, Dodge JL, Bacchetti P, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG.

Clin Infect Dis. 2017 Nov 29;65(12):2050-2056. doi: 10.1093/cid/cix716.

28.

Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women.

Sarkar M, Dodge JL, Greenblatt RM, Kuniholm MH, DeHovitz J, Plankey M, Kovacs A, French AL, Seaberg EC, Ofotokun I, Fischl M, Overton E, Kelly E, Bacchetti P, Peters MG; Women’s Interagency HIV Study.

Clin Infect Dis. 2017 Oct 30;65(10):1695-1702. doi: 10.1093/cid/cix643.

29.

The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.

Keating SM, Dodge JL, Norris PJ, Heitman J, Gange SJ, French AL, Glesby MJ, Edlin BR, Latham PS, Villacres MC, Greenblatt RM, Peters MG; Women’s Interagency HIV Study.

PLoS One. 2017 Sep 13;12(9):e0181004. doi: 10.1371/journal.pone.0181004. eCollection 2017.

30.

Management of Autoimmune Hepatitis in Pregnant Women.

Peters MG.

Gastroenterol Hepatol (N Y). 2017 Aug;13(8):504-506. No abstract available.

31.

Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.

Price JC, Dodge JL, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski S, Tien PC.

AIDS. 2017 Sep 24;31(15):2119-2125. doi: 10.1097/QAD.0000000000001601.

32.

New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.

Peters MG, Locarnini S.

Gastroenterol Hepatol (N Y). 2017 Jun;13(6):348-356.

33.

Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.

Naggie S, Marks KM, Hughes M, Fierer DS, Macbrayne C, Kim A, Hollabaugh K, Roa J, Symonds B, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Chung R; AIDS Clinical Trials Group (ACTG) A5327 Study Team.

Clin Infect Dis. 2017 Apr 15;64(8):1035-1042. doi: 10.1093/cid/cix025.

34.

Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections.

Vergara C, Thio C, Latanich R, Cox AL, Kirk GD, Mehta SH, Busch M, Murphy EL, Villacres MC, Peters MG, French AL, Golub E, Eron J, Lahiri CD, Shrestha S, Gustafson D, Young M, Anastos K, Aouizerat B, Kim AY, Lauer G, Thomas DL, Duggal P.

Genes Immun. 2017 Mar;18(2):82-87. doi: 10.1038/gene.2017.2. Epub 2017 Mar 16.

35.

Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation.

Liu J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz O, Gee Lim S, Marins EG, Mishra P, Peters MG, Miller V.

J Virus Erad. 2017 Jan 1;3(1):1-6.

36.

Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.

Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG.

Clin Infect Dis. 2017 May 1;64(9):1283-1288. doi: 10.1093/cid/cix129. Review.

37.

Sonography Predicts Liver Steatosis in Patients With Chronic Hepatitis B.

Kelly EM, Feldstein VA, Etheridge D, Hudock R, Peters MG.

J Ultrasound Med. 2017 May;36(5):925-932. doi: 10.7863/ultra.16.04076. Epub 2017 Feb 2.

PMID:
28151547
38.

Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria.

Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S.

Mod Pathol. 2017 May;30(5):773-783. doi: 10.1038/modpathol.2016.267. Epub 2017 Jan 20.

39.

Screening for hepatocellular carcinoma: What is missing?

Mehta NJ, Celik AD, Peters MG.

Hepatol Commun. 2016 Dec 19;1(1):18-22. doi: 10.1002/hep4.1014. eCollection 2017 Feb. Review.

40.

Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.

Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC.

Hepatology. 2017 Mar;65(3):853-863. doi: 10.1002/hep.28968. Epub 2017 Feb 3.

41.

Sex differences in the association of HIV infection with hepatic steatosis.

Kardashian A, Ma Y, Scherzer R, Price JC, Sarkar M, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC.

AIDS. 2017 Jan 28;31(3):365-373. doi: 10.1097/QAD.0000000000001334.

42.

Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma.

Ecker BL, Peters MG, McMillan MT, Sinnamon AJ, Zhang PJ, Kelz RR, Roses RE, Drebin JA, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2017 Feb;24(2):425-433. doi: 10.1245/s10434-016-5641-1. Epub 2016 Oct 26.

PMID:
27785659
43.

Preoperative radiotherapy in the management of retroperitoneal liposarcoma.

Ecker BL, Peters MG, McMillan MT, Sinnamon AJ, Zhang PJ, Fraker DL, Levin WP, Roses RE, Karakousis GC.

Br J Surg. 2016 Dec;103(13):1839-1846. doi: 10.1002/bjs.10305. Epub 2016 Sep 29.

PMID:
27682864
44.

Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study.

Desai SN, Dodge JL, Landay AL, Glesby MJ, Latham PS, Villacres MC, French AL, Gange SJ, Greenblatt RM, Peters MG.

Medicine (Baltimore). 2016 Aug;95(33):e4483. doi: 10.1097/MD.0000000000004483.

45.

Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.

Castillo LF, Tascón R, Lago Huvelle MR, Novack G, Llorens MC, Dos Santos AF, Shortrede J, Cabanillas AM, Bal de Kier Joffé E, Labriola L, Peters MG.

Oncotarget. 2016 Sep 13;7(37):60133-60154. doi: 10.18632/oncotarget.11107.

46.

Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.

Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V 3rd, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R; North American AIDS Cohort Collaboration on Research and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA.

Clin Infect Dis. 2016 Nov 1;63(9):1160-1167. Epub 2016 Aug 9.

47.

Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus-coinfected Women.

Kelly EM, Dodge JL, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG.

Clin Infect Dis. 2016 Aug 15;63(4):512-8. doi: 10.1093/cid/ciw350. Epub 2016 May 25.

48.

Use of Palliative Care Consultation for Patients with End-Stage Liver Disease: Survey of Liver Transplant Service Providers.

Beck KR, Pantilat SZ, O'Riordan DL, Peters MG.

J Palliat Med. 2016 Aug;19(8):836-41. doi: 10.1089/jpm.2016.0002. Epub 2016 Apr 19.

49.

Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.

Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):660-7. doi: 10.1089/aid.2015.0236. Epub 2016 Mar 14.

50.

Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection.

French AL, Hotton A, Young M, Nowicki M, Augenbraun M, Anastos K, Seaberg E, Rosenberg W, Peters MG.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):274-80. doi: 10.1097/QAI.0000000000000969.

Supplemental Content

Loading ...
Support Center